# US 2026/0097109 A1 · HPV Virus-Like Particle Bioconjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097109 A1
- Document ID: US20260097109A1
- Status: Published application
- Kind: A1
- Application number: 19/352,201
- Filed: 2025-10-07
- Published: 2026-04-09
- Earliest claimed: 2024-10-07
- Assignees: Inventprise, LLC
- Applicants: Inventprise, Inc.
- Inventors: Subhash V. Kapre
- Web page: https://patentgrep.com/patent/US20260097109A1

## CPC

- A61K 39/12: Viral antigens
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6075: {Viral proteins}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention is directed to immunogenic composition, vaccines and conjugates comprising virus-lie particles (VLP) compositions conjugated to one or more L2 proteins of HPV. The invention further includes methods for the manufacture of immunogenic compositions and vaccines and methods for the treatment and/or prevention of HPV infection.

## Claims

### Claim 1

An immunogenic composition comprising virus-like particles (VLPs) of HPV L1 protein conjugated to one or more types of HPV L2 protein.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the one or more types of HPV L2 protein comprise five or more, ten or more, fifteen or more, or twenty or more different antigenic types of L2 protein.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, further comprising a carrier protein.

### Claim 4 (depends on 3)

The immunogenic composition of claim 3, wherein the carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, B. Pertussis proteins, Pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein, Human Papilloma viral protein antigens, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof.

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, further comprising one or more hetero-or homo-bifunctional or multifunctional spacer arms.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, further comprising an adjuvant.

### Claim 7 (depends on 6)

The immunogenic composition of claim 6, wherein the adjuvant comprises aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, TLR ligands, and/or a potent TLR4/7/8/9 agonists.

### Claim 8 (depends on 7)

The immunogenic composition of claim 7, wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and/or aluminum hydroxide.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1, wherein the VLPs comprise L1 proteins of HPV serotypes 16 and/or 18.

### Claim 10 (depends on 1)

The immunogenic composition of claim 1, wherein the one or more types of HPV L2 protein comprise serotypes 6, 11, 16, 18, 31, 33, 45, 52, and/or 58.

### Claim 11 (depends on 1)

A method of manufacture of the composition of claim 1 comprising:
providing VLPs of HPV L1 protein;
providing HPV L2 proteins;
conjugating the VLPs with the HPV L2 proteins, or antigenic portions thereof, with an enzyme forming the composition; and
isolating the composition.

### Claim 12 (depends on 12)

The method of claim 12, further comprising adding an adjuvant.

### Claim 13 (depends on 12)

The method of claim 12, further comprising adding a carrier protein.

### Claim 14 (depends on 12)

The method of claim 12, further comprising adding a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method of treating or preventing an HPV infection comprising:
administering the composition of claim 1 to a patient in need thereof.
